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Abstract 
The use of the anticancer drug melphalan is limited due to its poor water solubility. To address such 
limitation, it is incorporated within a novel delivery system using β-cyclodextrin-gemini surfactants 
(18:1βCDg). Herein, two fast and simple FIA-MS/MS methods are developed for the quantification 
of melphalan (Mel) within the drug delivery system so that the solubilization efficiency of the system 
can be assessed. FIA-MS/MS methods are developed using a triple quadrupole-linear ion trap mass 
spectrometer, equipped with electrospray ionization (ESI) in the positive ion mode. A deuterated form 
of melphalan (melphalan-d8) was used as an internal standard (IS). The methods were validated 
according to the FDA guidance. A linearity in the range of 2–100 ng/mL and accuracy and precision 
below 15% were observed for all standard points and quality control samples. The intra- and inter-day 
variations, freeze-thaw stability were within the acceptable range according to the criteria set by 
regulatory guidelines. On the other hand, other stability measures, such as room temperature stability 
and long term stability did not meet the required guidelines in some cases, indicating the need for 
quick sample analysis upon preparation. Such a fact could have been overlooked if full method 
validation was not performed. The developed methods were applied to determine the 
encapsulation/solubilisation of [18:1βCDg\Mel] delivery system. 18:1βCDg enhances the aqueous 
solubility of melphalan without the need for co-solvent. The highest melphalan solubility was 
observed at the 18:1βCDg\Mel complex molar ratio  of 2:1.  This study demonstrated that a fast 
analysis for the purpose of quantifying a chemically unstable drug, such as melphalan is feasible and 
important for the development of commercial dosage forms.  
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1. Introduction  
Several effective chemotherapeutic agents, such as melphalan, show unfavourable solubility or 
stability due to their physiochemical properties that affect their therapeutic use.1-3 Melphalan (L-
phenylalanine mustard) (Figure 1-A) is an alkylating agent primarily used in the management of multiple 
myeloma and as an adjunctive therapy in regionally in-transit metastatic melanoma.4 It is a lipophilic drug 
with low aqueous solubility, requiring the use of a co-solvent (namely, propylene glycol) for parenteral 
administration. Propylene glycol can cause adverse effects when used in high concentrations, including, 
nephrotoxicity, cardiac arrhythmia, and metabolic acidosis.5 In addition to poor solubility, melphalan 
shows minimal chemical stability in aqueous medium as it hydrolyzes into hydroxymelphalan.6 
Therefore, attempts to improve melphalan’s solubility and stability were conducted by either chemical 
modifications or by engineering novel drug delivery systems, such as nano-systems.7-10    
Nanotechnology is being applied for developing novel therapies that can improve the solubility of 
poorly soluble drugs.11 For example, cyclodextrin-based drug delivery systems have been widely 
investigated to improve the delivery of melphalan as well as other chemotherapeutics.12-15 β-Cyclodextrin 
(β-CD) is a natural product with low toxicity.16 It has the ability to enhance the delivery of hydrophobic 
drugs by forming gust-host complexes.16 β-CD has cyclic ring structure containing seven D-(+) 
glucopyranose units attached by a-(1,4) glucosidic bonds which create a lipophilic inner cavity and 
hydrophilic outer surface. Such architecture creates a moiety capable of interacting with a large variety of 
guest molecules to form non-covalent inclusion complexes. To enhance the drug delivery capacity of the 
β-CD, we conjugated the molecule to gemini surfactants moieties. Gemini surfactants are composed of 
two hydrophobic portions, commonly quaternary amines, and two hydrophobic portions with the two 
polar groups connected via a spacer region. They have the ability to interact electrostatically with the 
negatively charged cell surface, enhancing cellular uptake of the delivery system17. 
The resulting conjugate, 18:1-7NβCD-18:1 (18:1βCDg) (Figure 1-C) combines the encapsulation 
properties of β-CD and the cell-penetrating ability of cationic gemini surfactants.18-20 This novel drug 
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delivery system can incorporate lipophilic drugs, such as melphalan, into the β-CD moiety and form 
nanoplatform.21 Recently, we showed the efficiency of β-CD-modified gemini surfactant (12βCDg) in 
improving the delivery of melphalan in melanoma cell line.22 The IC50 of melphalan improved 
significantly and demonstrated efficiency in melphalan- resistant melanoma. To optimize the stability of 
the complex and to maximize the solubilisation efficiency, various analytical methods were developed. 
Higuchi and Connors described an analytical approach to study the CD/drug solubility relationship known 
as the phase-solubility method.23 This method examines the effect of the solubilizer (CD or a ligand) on 
the drug being solubilized (the substrate). Therefore, the development of analytical methods to determine 
the encapsulation/solubilisation efficiency of the β-CD moiety is critical in the development of efficient 
β-CD modified drug delivery system.  
Numerous high-performance liquid chromatography (HPLC) analytical methods have been 
developed to quantify melphalan in pharmaceutical and biological systems for pharmacokinetic and 
quality control studies.24-30 For instance, Cummings and co-workers described an HPLC method for the 
determination of nitrogen mustard compounds, including melphalan, in plasma samples after chemical 
derivatization process with diethyldithiocarbamic acid (DDTC).29 C18 column was used with a linearity 
range of 0.1 – 100 g/mL. However, this method lacked sensitivity and required long sample preparation 
time (30 min) with a run time of 14.6 minutes. Pinguet et al developed a simplified HPLC method, 
requiring 3.3. min run time.30 Despite improvements, the lower limit of quantification (LLOQ) at 20 
ng/mL may not be sufficient for many pharmaceutical applications. To improve melphalan quantification, 
mass spectrometry (MS) have also been used.31-35 A rapid HPLC-MS method for the quantification of 
melphalan in serum and plasma demonstrated a retention time of ≈ 2 min with LLOQ of 2 ng/mL.32 
However, the method requires a relatively complicated extraction procedure with specialized 
instrumentation (96 well solid phase extraction (SPE) blocks). The use of HPLC-tandem mass 
spectrometry (MS/MS) was reported by Mirkou and colleagues using two different HPLC 
conditions/columns and two extraction methods.33 In the first method, a cold methanol protein 
(4) 
 
precipitation is applied prior to injection onto a C18 column while the second one was based on solid 
phase extraction followed by hydrophilic interaction chromatography (HILIC)-MS/MS. The linearity of 
the methods were 1-500 ng/mL and 25-200 ng/mL, respectively with ≈ 7 min retention time in both cases.  
Despite the wide use of HPLC-MS, a simpler MS-based approach for quantification is flow 
injection analysis-tandem mass spectrometry (FIA)-MS/MS in which the analytical column is removed 
and quantification is reliant on MS response in multiple reaction monitoring mode (MRM). (FIA)–
MS/MS has been widely utilized as a simple and high throughout methods in comparison to LC-
hyphenated techniques. It provides cost and time effective strategy that have been explored for the 
analysis of pharmaceuticals in different matrices.36-39 For example, a fully validated simple FIA-MS/MS 
method was recently developed to quantify metformin in dog serum.36  The method was simple and fast 
(2 min run time), achieving a sensitivity comparable to the relatively complicated conventional HPLC-
MS/MS methods.40,41 The main shortcoming of FIA, however, is seen in complex matrices, particularly 
with multi-analyte analysis in which the linearity range of the method can be affected. In addition, the 
removal of the LC column can cause saturation of the MS detector with either the analyt(s) or matrix 
components, which can negatively affect method sensitivity.42 However, the advances in sample 
extraction techniques and in ionization efficiency (especially in ESI and nano-ESI) can overcome such 
hurdles, which is reflected in the large number of methods employing FIA.43     
In this paper, we developed and validated a rapid and simple FIA–MS/MS methods that were 
applied for the quantification of melphalan in 18:1βCDg surfactant formulations. The methods were used 
to assess the solubilisation efficiency of 18:1βCDg as a potential drug delivery system for melphalan.  
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Figure 1: chemical structure of (A) melphalan, (B) melphalan-d8 and (C) 18:1-7NβCD-18:1 
(18:1βCDg)  gemini surfactant 
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2. Material & Methods 
2.1. Materials and apparatus  
Melphalan (Mel, 99 %Purity) was purchased from Sigma-Aldrich (Oakville, ON, Canada). Melphalan-d8 
dihydrochloride (Mel-d8), used as internal standard (IS), was purchased from Toronto Research 
Chemicals Inc (Toronto, ON, Canada). Synthesis and characterization of 18:1-7NβCD-18:1 gemini 
surfactant was previously described.20,21 Formic acid was purchased from EMD (Gibbstown, NJ,USA). 
Water (LC-MS grade), acetonitrile (LC-MS grade) and Dimethyl Sulfoxide DMSO (Certified ACS) were 
purchased from Fisher (Ottawa, ON, CA). Chemical structure of the drug, IS and 18:1βCDg are shown in 
Figure 1.  
2.2. Standard Preparation  
2.2.1. Method #1:  
Stock solutions of melphalan (1 mg/mL) was prepared in 10% acidified ethanol (0.1% HCl), to achieve 
complete aqueous solubility, and stored at - 80 °C. Fresh standard solutions were prepared daily by serial 
dilutions in water (LC/MS grade) to eight standard points in a range from 3 ng/mL to 100 ng/mL .The 
stocks of standard solutions were stored at -80 °C for method validation. A stock solution of Melphalan-
d8 (1 mg/mL) in DMSO was prepared and stored at -20 °C. Working stock of melphalan-d8 (4 µg/mL in 
DMSO) was prepared daily and 10 µL was added to each standard and sample to a final concentration of 
40 ng/mL. The purpose of this method is to compare the solubility of melphalan between acidified 
aqueous solution and the 18:1βCDg gemini surfactant formulations (i.e. control).  
2.2.2. Method #2:  
Method#2 was developed to quantify the analyte in lipid-based drug delivery systems. Stock solution of 
melphalan (1 mg/mL) was prepared in acidified ethanol (0.1% HCl). An appropriate volume of melphalan 
solution was mixed with 18:1βCDg gemini surfactant aqueous solution to yield a final molar ratio of 2:1 
[18:1βCDg-to-Mel]. 18:1βCDg\Mel formulation were frozen at -80 °C for 2 h. After freezing, the 
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formulation was transferred to a Labconco® Freezone Plus 6 L cascade freeze dryer (Labconco, Kansas 
City, MO,USA) at -80 °C and 0.03 mBar vacuum and lyophilized for 24 h.  Lyophilized formulations 
were rehydrated to a final concentration of 1mg/mL melphalan. Eight standard points in a range from 3 
ng/mL to 100 ng/mL (melphalan) were prepared. Melphalan-d8 (IS) were spiked in all standards at final 
concentration of 40 ng/mL. The stocks of standard solutions were stored at -80 °C for method validation.  
2.3. Mass Spectrometry conditions 
FIA–MS/MS methods were developed and validated using a 1200 Agilent High Performance Liquid 
Chromatography (HPLC) system (Mississauga, ON, CA) interfaced by connector to an ABSciex QTRAP 
4000, a hybrid quadrupole linear ion trap mass spectrometer (Q-LIT), equipped with a Turbo-V 
IonSpray®  electrospray ionization (ESI) source (Concord, ON, CA). ABSciex Analyst software (Version 
1.6.0) was used for system control and quantification.  
Sample injection was performed using 1200 Agilent auto-injector set to 4 °C and 2 µL of each sample 
was delivered with isocratic mobile phase consisting of water/acetonitrile (50:50, v/v) with 0.1% formic 
acid at a flow rate of 0.2 mL/min for a run time of 2 minutes. Multiple reaction monitoring (MRM) was 
achieved using (ESI) source in the positive ion mode. Source temperature was set to 600 C, ion spray 
voltage (ISV) 5500 V, curtain gas (CUR) 40, nebulizer gas (GS1) 40, heater gas(GS2) 40, collision gas 
(CAD) 6 and using an exit potential of 16 V for all MRM transitions. Dwell time for all transitions was 
150 ms at unit resolution. Nitrogen was used as the gas for all cases. Table 1 summarizes the monitored 
ion transitions, for both the analyte and the internal standard, and the corresponding MS conditions. 
Acceptance criteria for the ratio between the quantifier/qualifier ions was set at ±20% as 
recommended by the Commission of the European communities44. In fact all our acquired data 
showed variations less than 7% expect for two points showing 13% and 18%. 
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 Melphalan Melphalan-d8 (IS) 
305  168 
(Quantification) 
305  246 
(Conformation)  
314  172 
(Quantification) 
314  254 
(Conformation) 
De-clustering potential (DP) 55 50 56 52 
Collision energy (CE) 45 33 38 35 
Collision exit potential (CXP) 16 16 16 16 
Table 1: MRM transitions for melphalan and melphalan-d8 (IS) and optimized MS conditions  
 
2.4. Method Validation  
FDA Guidance for Bioanalytical Method Validation was used as a guideline to validate both FIA-MS/MS 
methods,45 to ensure the a validity of the quantitative data. The following parameters were evaluated for 
method validation:  selectivity, accuracy, precision, sensitivity, recovery, reproducibility, matrix effect, 
dilution integrity and stability.  
Selectivity was tested at the lower limit of quantification (3 ng/mL) for the ability to distinguish the 
analyte in the presence of other components in the formulation. Five sets of the formulation were used.  
A standard (calibration) curve of eight concentration points, ranging from 3 ng/mL to 100 ng/mL , were 
constructed for each method by determining the best fit of peak area ratios (peak area ratio of the analyte 
to internal standard) versus the analyte concentration. A linear regression analysis weighing the standard 
curve with 1/X was applied for best fit.  
To evaluate the accuracy and precision of the standard curve, five replicate of each quality control (QC) 
sample (LLOQ = 3 ng/mL, low QC (LQC) = 9 ng/mL, middle QC (MQC) = 35 ng/mL and high QC 
(HQC) = 80 ng/mL) were used. Accuracy of QCs passed only if the mean values of the QC were within 
15% of the actual concentration except for (LLOQ) where it should be ±20% of the nominal value. For 
precision, each value of QC replicates must not exceed 15% of the coefficient of variation (CV) except 
for (LLOQ) where is should be ±20% of the CV. Inter- and intra-day accuracy and precision were also 
evaluated in a similar manner.  
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Dilution integrity was evaluated to assess the effect of dilution on the accuracy and precision of undiluted 
sample. Formulations were prepared without the drug as described above and spiked with 1 µg/mL of the 
drug. Spiked samples were then diluted with acidified water to 100 ng/mL (10x) and 10 ng/mL (100x).  
The stability of melphalan in formulation matrix was tested using freshly prepared calibration curve and 
QC samples for a) short-term stability (at bench top and auto-sampler); b) long-term stability at -80 °C; 
and c) freeze / thaw stability. A set of five replicates of each QC were prepared for each stability 
evaluation. For bench top short-term stability, samples stored at room temperature for 12 and 24 hr and 
re-analyzed. Another set of QC samples were prepared and analyzed then stored in the auto-sampler for 
24 h at 4 °C and reinjected. QC samples for the freeze / thaw stability were stored in the −80 °C freezer 
and were subjected to three freeze–thaw cycles. The samples were allowed to thaw completely and 
remained at room temperature for at least 1 h. Then samples were re-analyzed and returned to the −80 °C 
freezer for the next freeze–thaw cycle. The long-term stability was conducted on QC samples stored at 
−80 °C for 30 days.  
2.5. Method Application, Solubility Evaluation 
The developed methods were used to determine the solubilizing efficiency of cyclodextrin-modified 
gemini surfactant. 18:1βCDg\Mel formulations were prepared in different carrier-to-drug molar ratios 
(0:1, 1:1, 2:1, 3:1 and 5:1) as shown in Table 2. First, gemini surfactant stock solutions were prepared. 
Then, 1 mg of melphalan powder was added to each vial and placed in orbital shaker for 1 hour. Samples 
were subsequently lyophilized as described above. Upon freeze drying, samples were re-hydrated with 1 
mL water and filtered through 0.45 µM syringe filter to remove any insoluble melphalan. Samples were 
diluted 100X in acidified water and IS spiked in each sample to a final concentration of 40 ng/mL.  For 
samples containing free drug, Method 1 was used to quantify the analyte and for samples containing 
melphalan:18:1βCDg complex, Method 2 was used.  
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Formulation 
ID 
Molar Ratio 
18:1βCDg/Mel  
Amount of 18:1βCDg 
mg (Molarity) 
Amount of melphalan 
mg (Molarity) 
1 0:1 0 1 (3.28 mM) 
2 1:1 6.49 (3.28 mM) 1 (3.28 mM) 
3 2:1 12.98 (6.56 mM) 1 (3.28 mM) 
4 3:1 19.47 (9.84 mM) 1 (3.28 mM) 
5 5:1 32.41 (16.4 mM) 1 (3.28 mM) 
 
Table 2: molar rations of 18:1βCDg\Melphalan formulations evaluated in this work  
 
3. Results and Discussion 
3.1. Method development and selectivity  
The main purpose of this work is to develop fast and simple FIA-MS/MS quantification methods 
for melphalan by removing the need for chromatographic separation while solely utilizing the MRM 
capability of the MS instrument, ensuring specificity and selectivity. In addition, no extraction process 
was needed for the drug from the formulation, indicating the simplicity of the analytical procedure. The 
methods were developed to assess the novel β-CD modified drug delivery system 18:1βCDg and for 
quality control purposes.  
To ensure the robustness of the methods that are reliant only on the MS, the following strategies 
were adopted. First, two MRM transitions were selected and the monitored product ions for melphalan 
were diagnostic with relatively high abundance [Figure 2]. In addition, the MS conditions (i.e. DP, CE 
and CXP) were optimized for each MRM transition to ensure the ions stability and abundance [Table 1].  
Second, a deuterated melphalan analogue that bears 8 deuterium atoms (melphalan-d8) was used as 
an internal standard to account for any possible effects of formulation excipients/drug delivery system on 
the ionization and quantification of the drug. The internal standard (melphalan-d8) was spiked into 
standard curve samples, the QCs, and experimental samples to give a final concertation of 40 ng/mL prior 
to sample analysis. The similarity in the physicochemical properties of the deuterated internal standard 
(melphalan-d8) to the analyte (melphalan) confirmed the validity of the data and prevented any crosstalk 
between the two molecules. Figure 2 shows the MS/MS spectra of melphalan (Figure 1A) and the internal 
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standard melphalan-d8 (Figure 1B) and the proposed structures of the selected product ions. The ion 
observed at m/z 168 for melphalan and at m/z 172 for melphalan-d8 are the most abundant ions in the 
spectra and they were selected as the MRM transition for quantification. The second MRM transition, 305 
 246 for melphalan and 314  254 for melphalan-d8, were used as a confirmation transitions.   
Finally, two FIA-MS/MS methods were developed and validated in this work: method#1 to 
quantify melphalan in aqueous solution with the use of a co-solvent and method#2 to quantify the drug 
from 18:1βCDg delivery system to eliminate any possible interferences caused by formulation excipients. 
A typical FIA-MS/MS chromatogram for a double blank of 18:1βCDg drug delivery system (control: not 
spiked with melphalan nor internal standard) is presented in Figure 3A. It shows no interference from the 
drug delivery system components at the analyte/internal standard retention time (0.17 min) or during the 
full run time (2 min). Similar observations were reported during the construction of standard curve at 
different melphalan concentrations.  
 
 
 
(12) 
 
 
 
 
  
(A) 
[i] m/z 168 [ii] m/z 246 
m/z 305 
N
Cl
Cl
OH
O
NH3
+
N
Cl
Cl
CH3
H
+
N Cl
CH2
H
+
 
(13) 
 
 
  
Figure 2: MSMS spectra of [M+H]+ of melphalan (A) and the internal standatd melphalan-d8 (B), the product ions used in MRM are shown  
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Figure 3: FIA-MS/MS chromatograms for method#2 (A) double blank 18:1βCDg drug delivery system (B) 18:1βCDg drug delivery system 
spiked with melphalan (10 ng/mL) and melphalan-d8 (40 ng/mL)  
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3.2. Linearity and sensitivity  
An 8-point standard curve was constructed (Figure 4, Method#1) by calculating the peak area ratio 
of melphalan to melphalan-d8 versus melphalan concentration and establishing a linear regression 
analysis weighting the standard curve with 1/X for best fit. The average correlation coefficient (n = 3) 
was found to be 0.9944 for method 1 and and 0.9991 for method 2. The LLOQ was 3 ng/mL and ULOQ 
was 100 ng/mL. Such values are ideal for the intended application and provide the needed quantitative 
power to assess the solubilization potential of the novel formulations without the need for tedious 
chromatographic separation.  
3.3. Accuracy and precision  
The precision and accuracy were evaluated according to the FDA guidelines and are shown in 
Tables 3 and 4. The LQC (9 ng/mL) was 3 fold higher than the LLOQ and the HQC was 80% of the 
ULOQ, as stipulated by the regulatory guidelines.  
The intra-day precision and accuracy (Table 3) of the methods were evaluated by running three sets 
of QCs in three different days with five replicates of each QC in each run. The accuracy was reported as a 
percentage of the theoretical concentration ranging from 89.89 to 103.73% for method 1 and from 89.07 
to 107.87% for method 2. The precision was also within the acceptable range as the coefficient of 
variation (CV%) was in the range of 1.69 – 9.35% and 0.9 – 10.39 % for methods 1 and 2, respectively.  
Similarly, the inter-day accuracy and precision data for the 15 replicates from the three-day runs 
yielded a precision in range of 1.08 and 5.56 %and accuracy between 93.62% and 101.56% for method # 
1. The inter-day precision and accuracy range for method # 2 were 1.49 to 6.43 and 93.9 to 100.47% 
respectively (Table 4). All these values were within the acceptable range according to the FDA 
guidelines.  
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3.4. Stability   
Determining the chemical stability of QC samples in different storage conditions is essential for 
ensuring the accuracy of the method. The suitability of the experimental and storage conditions are 
assessed. Stability of the QC samples at bench top (stability at room temperature) for 24 hrs results 
showed over 50% reduction in the initial concentration of all QC samples for both methods. This is 
expected as hydrolysis of melphalan is fast in an aqueous solution at room temperature.6,33  Stability of 
QCs in the auto-sampler (at 4 °C) for 24 hrs showed 30% reduction of the initial concentrations for all 
QCs for method#1. For method # 2, at auto-sampler condition (4 °C) for 24 hrs, the precision and 
accuracy for the 5 replicates were 93.2 % to 98.52 and 2.72 to 6.72%, respectively. Such data suggests the 
need for quick analysis of melphalan samples to ensure no loss of the analyte during the analysis; hence 
the value of developing fast FIA-MS/MS method.   
For the freeze-thaw stability, each batch of the QC samples was subjected to three freeze-thaw 
cycles. Upon the third cycle, the precision and accuracy were in the range of 93.55-102.8% and 5.01-
6.6%, respectively for method#1 in comparison to 92.67-104.22% and 3.32-6.38% for method#2. In both 
cases, the analyte was stable after three cycles of freezing and thawing, meeting the required regulatory 
criteria of ±15%.  
For the long term stability (35 days at -80 °C), the precision and accuracy failed to meet the FDA 
guidelines as more than 2 QCs in each level were out of the range of 15-20% for method#1. On the 
contrary, the precision and accuracy of QC replicates were between 91.7 to 100.6% and 3.34 to 8.76 for 
method#2. These results indicate that samples for method 2 can be stored up to one month at -80 without 
affecting the method’s validity. Such discrepancy between the two methods is most likely due to ability of 
β–CD to preserve the physiochemical stability of melphalan during freezing and storage.  
In summary, Method#2, with the 18:1βCDg/melphalan complexes, showed acceptable stability in all 
conditions, except for room temperature. However, significant instability was observed for method 1. As 
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a result, all experimental samples were freshly prepared and analyzed including the standard curve and 
QC samples to ensure the accuracy and the validity of the results.     
(19) 
 
 
 
Figure 4: A typical 8 points standard curve ranging from 3 ng/mL to 100 ng/mL with a regression coefficient of 0.9995 (Method # 1) 
(20) 
 
 
 
[Table 3]: Intra-day accuracy and precision 
 
  
 METHOD # 1 METHOD # 2 
QUALITY 
CONTROL Replicates Analysis day 
Observed concentration  
(mean ± SD; ng/mL) 
Precision 
(RSD%) 
Accuracy  
(%) 
Observed concentration  
(mean ± SD; ng/mL) 
Precision 
(RSD%) 
Accuracy 
(%) 
LLOQ  
(3 NG/ML) 
5 1 2.93 ± 0.13 4.59 97.67 3.24 ± 0.089 2.73 107.87 
5 2 3.11 ± 0 4.07 103.73 2.93 ± 0.3 10.39 97.60 
5 3 3.10 ± 0.08 2.67 103.27 2.88 ± 0.18 6.09 95.93 
        
LQC 
(9 NG/ML) 
5 1 9.04 ± 0.16 1.81 100.44 8.88 ± 0.08 0.9 98.62 
5 2 8.85 ± 0.15 1.69 98.311 8.02 ± 0.39 4.87 89.07 
5 3 8.92 ± 0.41 4.57 99.13 8.93 ± 0.35 3.92 99.27 
        
MQC 
(35 
NG/ML) 
5 1 33.14 ± 1.39 4.21 94.69 32.48 ± 1.79 5.5 92.8 
5 2 31.46 ± 1.31 4.18 89.89 33.42 ± 1.94 5.8 95.48 
5 3 33.7 ± 3.15 9.35 96.29 32.7 ± 1.50 4.59 93.43 
        
HQC 
(80 
NG/ML) 
  
5 1 77.64 ± 5.17 6.62 97.05 78.8 ± 4.88 6.19 98.5 
5 2 73.2 ± 4.87 1.88 91.5 78.26 ± 3.28 4.2 97.83 
5 3 81.82 ± 2.48 3.12 102.27 80.82 ± 2.66 3.29 101.03 
(21) 
 
 Method # 1 Method # 2 
Quality 
control 
Concentration 
(ng/mL) Replicates 
Observed concentration  
(mean ± SD; ng/mL) 
Precision 
(RSD%) 
Accuracy  
(%) 
Observed concentration  
(mean ± SD; ng/mL) 
Precision 
(RSD%) 
Accuracy 
(%) 
LLOQ 3 15 3.05 ± 0.10 3.32 101.56 3.01 6.43 100.47 
LQC 9 15 8.94 ± 0.09 1.08 99.3 8.61 5.97 95.65 
MQC 35 15 32.77 ± 1.17 3.56 93.62 32.87 1.49 93.9 
HQC 80 15 77.55 ± 4.31 5.56 96.94 79.29 1.7 99.12 
[Table 4]: Inter-day accuracy and precision   
(22) 
 
3.5.  Application 
Both methods described above were utilized to characterize and evaluate the 18:1βCDg delivery 
system as a potential carrier for melphalan. β-CD has the ability to form an inclusion complex with 
hydrophobic drugs.16 This property of β-CD has been employed widely in the pharmaceutical industry to 
increase the aqueous solubility of hydrophobic moieties with several β-CD-based formulations available 
in the market, such as VFEND® (voriconazole, an azole antifungal agent) and NEXTERONE® 
(amiodarone, an antiarrhythmic medication) among others, and hundred in clinical trials.16 Previously, our 
group reported that the βCD modified gemini surfactant (12 β CDgemini) are capable of forming 
guest/host complexes with a hydrophobic anticancer molecule.18  
To investigate the efficiency of the novel 18:1βCDg drug delivery system in increasing the 
solubility of melphalan, the validated methods were applied (Figure 5). 18:1βCDg\Mel complexes were 
prepared in different β-CD gemini (host) to melphalan (guest) molar ratios. At [0:1] ratio (i.e., without the 
use of 18:1βCDg) the aqueous solubility of melphalan was 203±16.60 µg/mL as determined by method 
#1. Increasing the molar ratio to [1:1] resulted in an almost 85% increase in melphalan’s solubility 
(377±16.4 µg/mL). The highest level of solubilization was achieved when the 18:1βCDg to Mel molar 
ratios was at [2:1], with melphalan solubility reaching 605±5 µg/mL which is more than two-fold increase 
compared to melphalan aqueous solution. Upon increasing the molar ratio above [2:1], a substantial 
reduction in melphalan’s solubility was observed at 450±6.5 µg/mL and 507±25.2 µg/mL for [4:1] and 
[5:1] molar ratios, respectively. We propose that at [2:1] 18:1βCDg\Mel molar ratio, two 18:1βCDg 
molecules encapsulate one melphalan molecule forming stable inclusion complexes leading to the higher 
solubilizing effect. This result is in  support of the previous model proposed by our group.18    
(23) 
 
 
 
Figure 5: Solubilization Efficiency of β-CD-gemini surfactant: determined by FIA-MS/MS analysis (n=3, ± SD) 
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4. Conclusion  
In this study, two FIA-MS/MS methods for melphalan were successfully developed and validated. The 
methods were applied for the determination of melphalan in novel 18:1βCDg drug delivery system. The 
simplicity and speed of the methods were appropriate with the requirement of efficient analytical 
approaches to quantify highly unstable drugs such as melphalan.  In fact, to process a batch of 96 samples 
will only require 5.6 hours and we demonstrated that the samples are stable in such timeframe within an 
autosampler of an HPLC system. The removal of the HPLC column did not affect the sensitivity, 
accuracy, and precision of the methods as they were validated according to FDA guidelines.  An 
important finding that could have been overlooked if a full validation was not conducted is the stability of 
the samples.  It was shown that fresh samples should be prepared and analyzed as various storage 
conditions resulted in degradation beyond the acceptable limit of 15%.  
The sensitivity and specificity of the methods allowed for the characterization of the solubility 
efficiency of a novel β-CD conjugated drug delivery system and it was shown that the solubility was 
significantly enhanced by 18:1βCDg delivery system. Such findings are critical as increasing the 
solubility of melphalan will enhance the bioavailability of the drug in a biological system and improve its 
chemotherapeutic effects. In addition, the results provide essential data in understanding the basic 
behavior governing the use of the novel drug delivery system, 18:1βCDg surfactants.  Currently, the 
pharmacokinetics of the formulation is being assessed in animal model using FIA-MS/MS and it will be 
reported upon completion.  
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